🔗 Visit the ClinicalTrials.gov page for NCT03113422
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. | Nat Med | 2013 | 8.89 |
| 2 | Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. | Mol Cancer Ther | 2013 | 1.60 |
| 3 | Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). | Blood Cancer J | 2015 | 0.82 |
| 4 | BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma. | Hematol Oncol | 2014 | 0.77 |